{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T16:19:42Z","timestamp":1793377182426,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:00:00Z","timestamp":1699574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:00:00Z","timestamp":1699574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Institutes of Health to the Children\u2019s Oncology Group","award":["U10CA098543"],"award-info":[{"award-number":["U10CA098543"]}]},{"name":"NCTN Statistics and Data Center Grant","award":["U10CA180899"],"award-info":[{"award-number":["U10CA180899"]}]},{"name":"NCTN Operations Center Grant","award":["U10CA180886"],"award-info":[{"award-number":["U10CA180886"]}]},{"name":"the NCORP grant","award":["UG1CA189955"],"award-info":[{"award-number":["UG1CA189955"]}]},{"DOI":"10.13039\/100006058","name":"St. Baldrick's Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006058","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020124","name":"Seagen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020124","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Chemotherapy-induced peripheral neuropathy (CIPN) is an under-recognized complication of several chemotherapy agents used as part of curative-intent therapy for Hodgkin Lymphoma (HL). In the absence of validated self- or proxy-report measures for children and adolescents, CIPN reporting has relied on clinician rating, with grading scales often restricted to severe manifestations. In a proof-of-concept study, we assessed the feasibility and psychometric performance of the Functional Assessment of Cancer Therapy-Gynecologic Oncology Group-Neurotoxicity (FACT-GOG-Ntx), a unidimensional CIPN symptom scale widely used adults with CIPN, in pediatric HL at risk for CIPN.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Youth (11+ years) and parents of all children (5\u201317.9\u00a0years) with newly diagnosed high-risk HL enrolled on Children\u2019s Oncology Group AHOD1331 (NCT02166463) were invited to complete the FACT-GOG-Ntx and a health-related quality of life (HRQL) measure at pre-treatment (Time 1), and during cycles 2 (Time 2) and 5 (Time 3) of chemotherapy during the first half of study accrual. Clinical grading of CIPN by providers was also assessed using the Balis Pediatric Neuropathy Scale. We evaluated Cronbach\u2019s alpha, construct validity, and agreement between raters. Change in FACT-GOG-Ntx scores over time was assessed using a repeated measures model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>306 patients had at least one completed FACT-GOG-Ntx with time-specific completion rates of\u2009&gt;\u200990% for both raters. Cronbach\u2019s alpha was\u2009&gt;\u20090.7 for youth and parent-proxy report at all time points. Correlations between FACT-GOG-Ntx and HRQL scores were moderate (0.41\u20130.48) for youth and parent-proxy raters across all times. Youth and parent-proxy raters both reported worse FACT-GOG-Ntx scores at Time 3 for those who had clinically-reported CIPN compared to those who did not. Agreement between raters was moderate to high. Compared to baseline scores, those at Time 3 were significantly lower for youth (\u03b2\u2009=\u2009\u2212\u20092.83, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and parent-proxy raters (\u03b2\u2009=\u2009\u2212\u20091.99, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>High completion rates at all time points indicated feasibility of eliciting youth and parent report. Psychometric performance of the FACT-GOG-Ntx revealed acceptable reliability, evidence of validity, and strong inter-rater agreement, supporting the use of this self- or proxy-reported measure of CIPN in youth with high-risk HL exposed to tubulin inhibitors, as part of a Phase 3 clinical trial.<\/jats:p>\n                <jats:p><jats:italic>Clinical trial information<\/jats:italic>: Clinical Trials Registry, NCT02166463. Registered 18 June 2014, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02166463\">https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02166463<\/jats:ext-link><\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41687-023-00653-0","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T07:01:51Z","timestamp":1699599711000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Performance of the FACT-GOG-Ntx to assess chemotherapy-induced peripheral neuropathy (CIPN) in pediatric high risk Hodgkin lymphoma: report from the Children\u2019s Oncology Group AHOD 1331 study"],"prefix":"10.1186","volume":"7","clinical-trial-number":[{"clinical-trial-number":"nct02166463","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0282-6490","authenticated-orcid":false,"given":"Susan K.","family":"Parsons","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angie Mae","family":"Rodday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglin","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank G.","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara O.","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara M.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon M.","family":"Castellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,10]]},"reference":[{"key":"653_CR1","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s11916-006-0032-0","volume":"10","author":"M Markman","year":"2006","unstructured":"Markman M (2006) Chemotherapy-induced peripheral neuropathy: underreported and underappreciated. Curr Pain Headache Rep 10:275\u2013278","journal-title":"Curr Pain Headache Rep"},{"key":"653_CR2","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1007\/s11136-013-0379-8","volume":"22","author":"EM Lavoie Smith","year":"2013","unstructured":"Lavoie Smith EM, Barton DL, Qin R et al (2013) Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 questionnaire. Qual Life Res 22:2787\u20132799","journal-title":"Qual Life Res"},{"key":"653_CR3","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1001\/jama.2015.0894","volume":"313","author":"B Diouf","year":"2015","unstructured":"Diouf B, Crews KR, Lew G et al (2015) Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA 313:815\u2013823","journal-title":"JAMA"},{"key":"653_CR4","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/cpt.1209","volume":"105","author":"B Diouf","year":"2019","unstructured":"Diouf B, Evans WE (2019) Pharmacogenomics of vincristine-induced peripheral neuropathy: progress continues. Clin Pharmacol Ther 105:315\u2013317","journal-title":"Clin Pharmacol Ther"},{"key":"653_CR5","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/S12094-010-0474-z","volume":"12","author":"G Gutierrez-Gutierrez","year":"2010","unstructured":"Gutierrez-Gutierrez G, Sereno M, Miralles A et al (2010) Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies. Clin Transl Oncol 12:81\u201391","journal-title":"Clin Transl Oncol"},{"key":"653_CR6","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1002\/pbc.23039","volume":"57","author":"DL Anghelescu","year":"2011","unstructured":"Anghelescu DL, Faughnan LG, Jeha S et al (2011) Neuropathic pain during treatment for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 57:1147\u20131153","journal-title":"Pediatr Blood Cancer"},{"key":"653_CR7","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1200\/JCO.2013.49.1514","volume":"31","author":"F Mols","year":"2013","unstructured":"Mols F, Beijers T, Lemmens V et al (2013) Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol 31:2699\u20132707","journal-title":"J Clin Oncol"},{"key":"653_CR8","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","volume":"13","author":"A Trotti","year":"2003","unstructured":"Trotti A, Colevas AD, Setser A et al (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176\u2013181","journal-title":"Semin Radiat Oncol"},{"key":"653_CR9","doi-asserted-by":"publisher","first-page":"E49","DOI":"10.1097\/NCC.0b013e318299ad23","volume":"36","author":"EM Lavoie Smith","year":"2013","unstructured":"Lavoie Smith EM, Li L, Hutchinson RJ et al (2013) Measuring vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia. Cancer Nurs 36:E49\u2013E60","journal-title":"Cancer Nurs"},{"key":"653_CR10","unstructured":"Cella D (1997) F.A.C.I.T. Manual. Manual of the functional assessment of chronic illness therapy (FACIT) scales (version 4)"},{"key":"653_CR11","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1023\/A:1006343818656","volume":"45","author":"TJ Postma","year":"1999","unstructured":"Postma TJ, Hoekman K, van Riel JM et al (1999) Peripheral neuropathy due to biweekly paclitaxel, epirubicin and cisplatin in patients with advanced ovarian cancer. J Neurooncol 45:241\u2013246","journal-title":"J Neurooncol"},{"key":"653_CR12","first-page":"741","volume":"13","author":"EA Calhoun","year":"2003","unstructured":"Calhoun EA, Welshman EE, Chang CH et al (2003) Psychometric evaluation of the functional assessment of cancer therapy\/gynecologic oncology group-neurotoxicity (Fact\/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 13:741\u2013748","journal-title":"Int J Gynecol Cancer"},{"key":"653_CR13","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1200\/JCO.2006.08.6652","volume":"25","author":"SR Land","year":"2007","unstructured":"Land SR, Kopec JA, Cecchini RS et al (2007) Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 25:2205\u20132211","journal-title":"J Clin Oncol"},{"key":"653_CR14","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.ygyno.2005.09.023","volume":"100","author":"HJ Long 3rd","year":"2006","unstructured":"Long HJ 3rd, Monk BJ, Huang HQ et al (2006) Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol 100:537\u2013543","journal-title":"Gynecol Oncol"},{"key":"653_CR15","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1200\/JCO.2012.44.8738","volume":"31","author":"DL Hershman","year":"2013","unstructured":"Hershman DL, Unger JM, Crew KD et al (2013) Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. J Clin Oncol 31:2627\u20132633","journal-title":"J Clin Oncol"},{"key":"653_CR16","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s12955-020-01493-y","volume":"18","author":"HL Cheng","year":"2020","unstructured":"Cheng HL, Lopez V, Lam SC et al (2020) Psychometric testing of the functional assessment of cancer therapy\/gynecologic oncology group-neurotoxicity (FACT\/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy. Health Qual Life Outcomes 18:246","journal-title":"Health Qual Life Outcomes"},{"key":"653_CR17","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1200\/JCO.20.03286","volume":"39","author":"ML Metzger","year":"2021","unstructured":"Metzger ML, Link MP, Billett AL et al (2021) Excellent outcome for pediatric patients with high-risk Hodgkin lymphoma treated with brentuximab vedotin and risk-adapted residual node radiation. J Clin Oncol 39:2276\u20132283","journal-title":"J Clin Oncol"},{"key":"653_CR18","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/S1470-2045(13)70501-1","volume":"14","author":"A Younes","year":"2013","unstructured":"Younes A, Connors JM, Park SI et al (2013) Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin\u2019s lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol 14:1348\u20131356","journal-title":"Lancet Oncol"},{"key":"653_CR19","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3322\/caac.21204","volume":"63","author":"SB Park","year":"2013","unstructured":"Park SB, Goldstein D, Krishnan AV et al (2013) Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin 63:419\u2013437","journal-title":"CA Cancer J Clin"},{"key":"653_CR20","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1200\/JCO.2013.52.5410","volume":"32","author":"DL Friedman","year":"2014","unstructured":"Friedman DL, Chen L, Wolden S et al (2014) Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children\u2019s Oncology Group Study AHOD0031. J Clin Oncol 32:3651\u20133658","journal-title":"J Clin Oncol"},{"key":"653_CR21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/bjh.16014","volume":"187","author":"KM Kelly","year":"2019","unstructured":"Kelly KM, Cole PD, Pei Q et al (2019) Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children\u2019s Oncology Group. Br J Haematol 187:39\u201348","journal-title":"Br J Haematol"},{"key":"653_CR22","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1177\/1043454218762705","volume":"35","author":"S Smolik","year":"2018","unstructured":"Smolik S, Arland L, Hensley MA et al (2018) assessment tools for peripheral neuropathy in pediatric oncology: a systematic review from the Children\u2019s Oncology Group. J Pediatr Oncol Nurs 35:267\u2013275","journal-title":"J Pediatr Oncol Nurs"},{"key":"653_CR23","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1056\/NEJMoa2206660","volume":"387","author":"SM Castellino","year":"2022","unstructured":"Castellino SM, Pei Q, Parsons SK et al (2022) Brentuximab vedotin with chemotherapy in pediatric high-risk Hodgkin\u2019s lymphoma. N Engl J Med 387:1649\u20131660","journal-title":"N Engl J Med"},{"key":"653_CR24","doi-asserted-by":"publisher","first-page":"6550","DOI":"10.1182\/blood-2022-167046","volume":"140","author":"SK Parsons","year":"2022","unstructured":"Parsons SK, Keller FG, Pei Q et al (2022) Peripheral neuropathy in children with high risk hodgkin lymphoma (HL): the role of protocol-stipulated dose modification in the children\u2019s oncology group (COG) AHOD1331 study. Blood 140:6550\u20136551","journal-title":"Blood"},{"key":"653_CR25","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R et al (2009) Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42:377\u2013381","journal-title":"J Biomed Inform"},{"key":"653_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL et al (2019) The REDCap consortium: building an international community of software platform partners. J Biomed Inform 95:103208","journal-title":"J Biomed Inform"},{"key":"653_CR27","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/j.1525-1438.2007.00794.x","volume":"17","author":"HQ Huang","year":"2007","unstructured":"Huang HQ, Brady MF, Cella D et al (2007) Validation and reduction of FACT\/GOG-Ntx subscale for platinum\/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study. Int J Gynecol Cancer 17:387\u2013393","journal-title":"Int J Gynecol Cancer"},{"key":"653_CR28","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3109\/10428194.2012.711830","volume":"54","author":"KJ Yost","year":"2013","unstructured":"Yost KJ, Thompson CA, Eton DT et al (2013) The functional assessment of cancer therapy-general (FACT-G) is valid for monitoring quality of life in patients with non-Hodgkin lymphoma. Leuk Lymphoma 54:290\u2013297","journal-title":"Leuk Lymphoma"},{"key":"653_CR29","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1477-7525-11-26","volume":"11","author":"AM Rodday","year":"2013","unstructured":"Rodday AM, Terrin N, Parsons SK (2013) Measuring global health-related quality of life in children undergoing hematopoietic stem cell transplant: a longitudinal study. Health Qual Life Outcomes 11:26","journal-title":"Health Qual Life Outcomes"},{"key":"653_CR30","volume-title":"Psychometric Theory","author":"J Nunnally","year":"1994","unstructured":"Nunnally J, Bernstein I (1994) Psychometric Theory, 3rd edn. McGraw-Hill Inc, New York","edition":"3"},{"key":"653_CR31","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s11136-011-9986-4","volume":"21","author":"SK Parsons","year":"2012","unstructured":"Parsons SK, Fairclough DL, Wang J et al (2012) Comparing longitudinal assessments of quality of life by patient and parent in newly diagnosed children with cancer: the value of both raters\u2019 perspectives. Qual Life Res 21:915\u2013923","journal-title":"Qual Life Res"},{"key":"653_CR32","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/jnci\/djab087","volume":"114","author":"MN Murugappan","year":"2022","unstructured":"Murugappan MN, King-Kallimanis BL, Reaman GH et al (2022) Patient-reported outcomes in pediatric cancer registration trials: a US food and drug administration perspective. J Natl Cancer Inst 114:12\u201319","journal-title":"J Natl Cancer Inst"},{"key":"653_CR33","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1007\/s00520-013-1748-0","volume":"21","author":"B Weber","year":"2013","unstructured":"Weber B, Largillier R, Ray-Coquard I et al (2013) A potentially neuroprotective role for erythropoietin with paclitaxel treatment in ovarian cancer patients: a prospective phase II GINECO trial. Support Care Cancer 21:1947\u20131954","journal-title":"Support Care Cancer"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-023-00653-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-023-00653-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-023-00653-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T07:06:35Z","timestamp":1699599995000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-023-00653-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,10]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["653"],"URL":"https:\/\/doi.org\/10.1186\/s41687-023-00653-0","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,10]]},"assertion":[{"value":"15 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NCI cIRB with local institutional review and approval prior to study opening.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Official sign off by COG, NCI (NCORP and CTEP), and industry partners.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"113"}}